For research use only. Not for therapeutic Use.
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation[1].
VUF11207 fumarate (0.17 nM; 5 days) inhibits RANKL‑ and TNF‑α‑induced osteoclastogenesis through CXCL12 inhibition in osteoclast precursor cells[1].
VUF11207 fumarate inhibits osteoclastogenesis by suppressing phosphorylation of erk[1].
VUF11207 fumarate (100 µg/day; s.c.; single daily for 5 days) inhibits LPS‑induced osteoclastogenesis, bone resorption and production of RANKL and TNF‑α in mice[1].
| Catalog Number | I017904 |
| CAS Number | 1785665-61-3 |
| Synonyms | (E)-but-2-enedioic acid;N-[(E)-3-(2-fluorophenyl)-2-methylprop-2-enyl]-3,4,5-trimethoxy-N-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide |
| Molecular Formula | C31H39FN2O8 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H35FN2O4.C4H4O4/c1-19(15-20-9-6-7-11-23(20)28)18-30(14-12-22-10-8-13-29(22)2)27(31)21-16-24(32-3)26(34-5)25(17-21)33-4;5-3(6)1-2-4(7)8/h6-7,9,11,15-17,22H,8,10,12-14,18H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b19-15+;2-1+ |
| InChIKey | MTPOECCHJLVVGO-FDULSSLPSA-N |
| SMILES | CC(=CC1=CC=CC=C1F)CN(CCC2CCCN2C)C(=O)C3=CC(=C(C(=C3)OC)OC)OC.C(=CC(=O)O)C(=O)O |
| Reference | [1]. Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92. [2]. Nugraha AP, et al. C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep. 2022 Mar;25(3):78. |
